Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

Ovensa Collaborates with Takeda to Deliver an Antibody to the Brain


AURORA, ON, March 21, 2019 /CNW Telbec/ - Ovensa Inc. ("Ovensa") is pleased to announce that it has entered into a collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") to evaluate Ovensa's proprietary nanomedicine platform called TRIOZANtm for the delivery of an antibody to the brain and evaluate its performance in a CNS disease model.

"We are extremely proud of this new partnership, which demonstrates a great deal of confidence in our unique delivery system which helps therapeutic molecules better cross the human body's various barriers such as the skin, the mucous membranes or the blood-brain barrier and reach their target. Takeda is the largest pharmaceutical company in Japan and is present in more than 70 countries. We are starting this collaboration with enthusiasm and hope that this partnership will accelerate the discussions we have with some 30 other companies, "says Ovensa's President and CEO, Mr. Stéphane Gagné.

Ovensa offers a platform allowing for the development of custom nanomedicines based on trimethylchitosan - a biopolymer derived from crustacean chitosan. Whether it is for reducing the side effects of chemotherapy, changing the expression of a gene that does not function normally or eliciting an optimal immune response of an antibody in the brain, the platform allows high engineering flexibility where nanomedicines are specifically designed to cross barriers and optimize tissue or cell targeting based on the disease.

Although Ovensa's platform research focuses on complex diseases for which there are few available treatments such as brain cancer and Alzheimer's Disease, it also applies to other therapeutic areas such as metabolic diseases, animal health or antibiotic resistance. Also using its patented TRIOZANtm platform, Ovensa is conducting trials with its collaborators to develop new custom nanomedicines using cannabinoids such as cannabidiol (CBD) to treat various diseases including certain cancers, diseases of the central nervous system and pain.

Terms of the agreement with Takeda have not been disclosed.

About Ovensa

Ovensa is a preclinical stage company fighting inherent therapeutic resistance in complex diseases by generating advanced nanotherapeutics using its proprietary TRIOZANtm Delivery Platform. The company focuses on advancing its lead candidate in glioblastoma as well as generating novel nanotherapeutic candidates in collaboration with pharmaceutical companies for applications in CNS and immuno-oncology.

 

SOURCE Ovensa


These press releases may also interest you

18 mai 2019
Healthpointe is pleased to announce the newest addition to their team of distinguished medical professionals: Dr. Anto T. A. Fritz. Dr. Fritz is fellowship trained in spine surgery, sports medicine, and foot & ankle. He will be practicing at...

18 mai 2019
Cook Medical and Ambu A/S have agreed on terms to enter into a partnership under which Cook will distribute Ambu's single-use, disposable duodenoscope in the U.S., following FDA clearance. The scope is currently being developed...

18 mai 2019
The Medicines Company today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of...

18 mai 2019
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will...

18 mai 2019
City College is a private not-for-profit college and is institutionally accredited by the Accrediting Bureau of Health Education Schools (ABHES). City College Altamonte Springs is located in Seminole County, Florida. Within fifty miles of the...

18 mai 2019
Janssen Pharmaceutical Companies of Johnson & Johnson presented new real-world data at the American Psychiatric Association (APA) 2019 Meeting which suggest that, among adult patients with major depressive disorder (MDD), psychiatric treatment in the...



News published on 21 march 2019 at 07:00 and distributed by: